Free Trial
NASDAQ:STAA

STAAR Surgical Q2 2025 Earnings Report

STAAR Surgical logo
$18.49 +0.73 (+4.11%)
Closing price 08/4/2025 04:00 PM Eastern
Extended Trading
$18.50 +0.02 (+0.08%)
As of 08/4/2025 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STAAR Surgical EPS Results

Actual EPS
N/A
Consensus EPS
-$0.56
Beat/Miss
N/A
One Year Ago EPS
N/A

STAAR Surgical Revenue Results

Actual Revenue
N/A
Expected Revenue
$40.93 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

STAAR Surgical Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

STAAR Surgical Earnings Headlines

A new rule goes live in July — and the banks are quietly crushing it
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
3 Reasons to Sell STAA and 1 Stock to Buy Instead
See More STAAR Surgical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like STAAR Surgical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on STAAR Surgical and other key companies, straight to your email.

About STAAR Surgical

STAAR Surgical (NASDAQ:STAA), together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

View STAAR Surgical Profile

More Earnings Resources from MarketBeat